Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA’s Human Drugs Program Suffers In Adjustment Of Agency Priorities

Executive Summary

President Trump's budget request would boost compounding and vaccines by $5m, but human drugs program would lose $4.8m in training funds.

You may also be interested in...



Woodcock Outlines Priorities For Next US FDA Commissioner

Along with the pandemic, user fees, IT upgrades and nutrition issues should be at the top of the list, the acting commissioner said.

Woodcock Outlines Priorities For Next US FDA Commissioner

Along with the pandemic, user fees, IT upgrades and nutrition issues should be at the top of the list, the acting commissioner said.

US FDA Personnel Costs Drop: Is The Next Generation Taking Over?

The agency sees its personnel compensation and benefits costs decrease for the first time in at least 16 years, while the overall FTE count continues to rise.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS141665

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel